This pilot study is to assess the efficacy and safety of BP1.4979 15 mg BID in female patients with moderate to severe binge eating disorder (BED), as defined according to DSM-5 guidelines.

开始日期2022-03-07

申办/合作机构

Bioprojet Pharma SARL

NCT03345953 / Terminated临床2期

Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)

This is a Group Sequential Test multicenter, randomized, double blind, placebo controlled phase II proof of concept trial with parallel groups to evaluate the efficacy and the safety of BP1.4979 15mg BID compared to placebo in RLS patients during 2 weeks double blind treatment.

开始日期2018-02-06

申办/合作机构

Bioprojet Pharma SARL

100 项与 BP-1.4979 相关的临床结果

登录后查看更多信息

100 项与 BP-1.4979 相关的转化医学

登录后查看更多信息

100 项与 BP-1.4979 相关的专利（医药）

登录后查看更多信息

项与 BP-1.4979 相关的文献（医药）

2019-06-01·Neuropsychopharmacology1区 · 医学

Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans

1区 · 医学

Article

作者: Mansouri, Esmaeil ; Duvauchelle, Thierry ; Houle, Sylvain ; Di Ciano, Patricia ; Boileau, Isabelle ; Robert, Philippe ; Le Foll, Bernard ; Wilson, Alan A ; Tong, Junchao ; Schwartz, Jean Charles

There has been considerable interest in the development of dopamine D3 receptor (DRD₃) partial agonists and antagonists for the treatment of substance use disorders. Pre-clinical evidence overwhelmingly supports the use of these drugs, but translation to humans has remained elusive due to the lack of selective compounds that are suitable for use in humans. Although it has been established for full antagonists, little in vivo occupancy data are available with DRD₃ partial agonists. Here we investigate for the first time in healthy controls, the in vivo occupancy of a novel D3 partial agonist (BP1.4979) at the DRD₃ and DRD₂. Participants received either a single dose (1, 3, 10 or 30 mg) or a subchronic regimen (5-7 days, q.d. or b.i.d) of BP1.4979, with the last dose given at 1, 12 or 24 h prior to scanning with [¹¹C]-(+)-PHNO. Single and subchronic administration of BP1.4979 dose-dependently occupied the DRD₃ and DRD₂, and this occupancy was preferential for the DRD₃, notably at longer time points after administration of BP1.4979. Also consistent with preference for the DRD₃, prolactin levels were minimally increased, and no subjective effects of BP1.4979 were reported. Serum levels of BP1.4979 were higher than its active metabolite, BP1.6239, while no notable increases in the inactive metabolite, BP1.6197, were found. These findings indicate the range of doses that can be used to occupy selectively the DRD₃ over the DRD₂ with BP1.4979 and speak to the use of in vivo imaging approaches in dose finding studies.

100 项与 BP-1.4979 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不宁腿综合征	临床3期	法国	Bioprojet Pharma SARL	2018-02-06
贪食症	临床2期	法国	Bioprojet Pharma SARL	2023-04-27
暴食症	临床2期	法国	Bioprojet Pharma SARL	2022-03-07
烟草依赖	临床1期	法国	Bioprojet Pharma SARL	2013-02-01